Anthropic IPO could reshape the AI infrastructure and drug discovery markets

A record-breaking public debut

Anthropic is preparing for an initial public offering (IPO) that could potentially break the current record for the largest IPO in history. This move marks a significant milestone for the artificial intelligence industry as it moves toward a global rollout phase. Analysts suggest that while the initial research phase is ending, the next stage of AI adoption could be significantly larger in scale.

The capital raised from this IPO is intended to fund one of the largest AI build-outs ever attempted. Anthropic aims to use these resources to improve the productivity of knowledge workers, a group that contributes more than $40 trillion in economic value worldwide. This massive expansion will require billions of dollars in infrastructure spending to support the growth of its models.

As the company goes public, the ripple effects will be felt across various sectors of the economy. Corporations that provide the underlying hardware and computing power are positioned to benefit from this influx of capital. Conversely, smaller companies that rely on a unique AI advantage may find their competitive edge shrinking as large-scale models become more accessible.

Broadcom's infrastructure windfall

Broadcom, a specialist in semiconductor design, is positioned as a primary winner from Anthropic's expansion plans. The company designs custom AI chips and has already established partnerships with major tech giants like Alphabet and Meta Platforms. Specifically, Broadcom has a long-term agreement to provide Tensor Processing Unit (TPU) compute capacity to Anthropic.

TPUs are custom AI chips that Broadcom co-designs with Alphabet to handle complex computations. The agreement between Anthropic and Broadcom is notable because it is non-cancellable, except in the event of a default, and is set to last for five years. The total value of this specific agreement is reported to be $161.2 billion, providing Broadcom with a stable and massive revenue stream.

Broadcom's financial outlook is tied closely to this AI growth, with the company projecting $115 billion in AI revenue for fiscal year 2027. This figure is expected to exceed the company's entire trailing 12-month revenue. While there are risks regarding lower gross margins as AI chips become a larger share of their business, the medium-term prospects remain attractive due to the scale of the Anthropic partnership.

The challenge for AI drug discovery

In contrast to the hardware boom, Recursion Pharmaceuticals faces a more difficult path forward. Recursion is a clinical-stage biotech company that uses an AI-powered operating system to screen drug candidates and automate parts of the clinical trial design process. The goal is to reduce the high costs and long timelines traditionally associated with bringing new medicines to market.

Despite its claims of a superior AI approach, Recursion has not yet brought a single drug to market since its founding in 2013. While clinical-stage drugmakers face strict regulatory hurdles, the lack of an approved program or a Phase 3 study is a point of concern for some analysts. The company has yet to prove that its specific AI operating system provides a distinct advantage over existing methods.

The rise of Anthropic presents a direct challenge to Recursion's niche. Anthropic already offers its large language model, Claude, to pharmaceutical companies to assist in drug discovery. According to Anthropic, nine of the 10 largest pharmaceutical companies are already clients contributing at least $100,000 in annual revenue. As these large models become standard tools, Recursion's unique advantage may disappear.

From research to global rollout

The transition from the research phase to the global rollout phase changes how the market values AI companies. For hardware providers like Broadcom, it means a shift toward massive, multi-year infrastructure contracts that provide predictable growth. For software and biotech firms, it means that the